Terms: = Lung cancer AND MDM2, HDM2, 4193, ENSG00000135679, HDMX, MGC71221, hdm2, Q00987 AND Clinical Outcome
11 results:
1. mdm2 gene amplification is associated with luminal breast cancer progression in humanized PDX mice and a worse outcome of estrogen receptor positive disease.
Wege AK; Rom-Jurek EM; Jank P; Denkert C; Ugocsai P; Solbach C; Blohmer JU; Sinn B; van Mackelenbergh M; Möbus V; Trumpp A; Marangoni E; Pfarr N; Irlbeck C; Warfsmann J; Polzer B; Weber F; Ortmann O; Loibl S; Vladimirova V; Brockhoff G
Int J Cancer; 2022 Apr; 150(8):1357-1372. PubMed ID: 34927257
[TBL] [Abstract] [Full Text] [Related]
2. Ki-67 Index of 55% Distinguishes Two Groups of Bronchopulmonary Pure and Composite Large Cell Neuroendocrine Carcinomas with Distinct Prognosis.
Milione M; Maisonneuve P; Grillo F; Mangogna A; Centonze G; Prinzi N; Pusceddu S; Garzone G; Cattaneo L; Busico A; Bossi P; Spaggiari P; Pellegrinelli A; Del Gobbo A; Ferrero S; Kankava K; Pruneri G; Rolli L; Roca E; Bercich L; Tironi A; Benvenuti MR; Gallazzi MS; Romano R; Berruti A; Pastorino U; Capella C
Neuroendocrinology; 2021; 111(5):475-489. PubMed ID: 32365350
[TBL] [Abstract] [Full Text] [Related]
3. Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC.
Kim Y; Lee B; Shim JH; Lee SH; Park WY; Choi YL; Sun JM; Ahn JS; Ahn MJ; Park K
J Thorac Oncol; 2019 Feb; 14(2):193-202. PubMed ID: 30391576
[TBL] [Abstract] [Full Text] [Related]
4. Association of p53 and mdm2 in the development and progression of non-small cell lung cancer.
Javid J; Mir R; Julka PK; Ray PC; Saxena A
Tumour Biol; 2015 Jul; 36(7):5425-32. PubMed ID: 25672611
[TBL] [Abstract] [Full Text] [Related]
5. A three-gene signature and clinical outcome in esophageal squamous cell carcinoma.
Sun LL; Wu JY; Wu ZY; Shen JH; Xu XE; Chen B; Wang SH; Li EM; Xu LY
Int J Cancer; 2015 Mar; 136(6):E569-77. PubMed ID: 25220908
[TBL] [Abstract] [Full Text] [Related]
6. The metastatic behavior of osteosarcoma by gene expression and cytogenetic analyses.
Salinas-Souza C; De Oliveira R; Alves MT; Garcia Filho RJ; Petrilli AS; Toledo SR
Hum Pathol; 2013 Oct; 44(10):2188-98. PubMed ID: 23845465
[TBL] [Abstract] [Full Text] [Related]
7. Novel targeted therapeutics: inhibitors of mdm2, ALK and PARP.
Yuan Y; Liao YM; Hsueh CT; Mirshahidi HR
J Hematol Oncol; 2011 Apr; 4():16. PubMed ID: 21504625
[TBL] [Abstract] [Full Text] [Related]
8. Association of p53 codon 72 polymorphism and mdm2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer.
Han JY; Lee GK; Jang DH; Lee SY; Lee JS
Cancer; 2008 Aug; 113(4):799-807. PubMed ID: 18618574
[TBL] [Abstract] [Full Text] [Related]
9. Meningioma: an update.
Lusis E; Gutmann DH
Curr Opin Neurol; 2004 Dec; 17(6):687-92. PubMed ID: 15542977
[TBL] [Abstract] [Full Text] [Related]
10. Prognostic factors in the so-called malignant mesenchymoma: a clinicopathological and immunohistochemical analysis.
Adachi T; Oda Y; Sakamoto A; Terashi T; Tamiya S; Hachitanda Y; Tsuneyoshi M
Oncol Rep; 2003; 10(4):803-11. PubMed ID: 12792727
[TBL] [Abstract] [Full Text] [Related]
11. Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas.
Gorgoulis VG; Zacharatos P; Mariatos G; Kotsinas A; Bouda M; Kletsas D; Asimacopoulos PJ; Agnantis N; Kittas C; Papavassiliou AG
J Pathol; 2002 Oct; 198(2):142-56. PubMed ID: 12237873
[TBL] [Abstract] [Full Text] [Related]
